About Monarch Bioimplants
Monarch Bioimplants is a company based in Root (Switzerland) founded in 2016 by Thomas Freier. Monarch Bioimplants has raised $24.93 million across 2 funding rounds from investors including FastTrack Ventures and Global Emerging Markets. Monarch Bioimplants operates in a competitive market with competitors including Avation, BioCircuit, Epineuron, Tulavi Nerve Therapeutics and Micro Leads, among others.
- Headquarter Root, Switzerland
- Founders Thomas Freier
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website monarchbioimplants.com
- Total Equity Funding$24.93M (USD)
in 2 rounds
- Latest Funding Round$23.41M (USD), Series B
Sep 2020
- InvestorsFastTrack Ventures
& 1 more
Funding Insights of Monarch Bioimplants
Monarch Bioimplants has successfully raised a total of $24.93M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $23.41 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.93M
- Total Rounds 2
- Last Round Series B — $23.41M
- First Round $1.52M
(Jul 2017)
- Investors Count 2
All 2 funding rounds of Monarch Bioimplants with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $23.41M | Series B | – | Global Emerging Markets | – |
| Jul 2017 | $1.52M | Seed | – | FastTrack Ventures | – |
2 investors in total: 2 institutional.
Investors in Monarch Bioimplants
Monarch Bioimplants has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include FastTrack Ventures and Global Emerging Markets.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | – | gemny.com | New York, United States | |
Investments in tech startups are managed by FastTrack Ventures. | 2015 | fasttrack.vc | Whistler, Canada |
Investor details for Monarch Bioimplants
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Monarch Bioimplants
1 people are tracked at Monarch Bioimplants (1 in leadership).
| Name | Role | Group |
|---|---|---|
Thomas Freier | Founder | Leadership |
Complete people profiles for Monarch Bioimplants
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Monarch Bioimplants
3 dated milestones of Monarch Bioimplants across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Monarch Bioimplants is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series B, of $23.4M.
Competitors of Monarch Bioimplants
Monarch Bioimplants operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avation, BioCircuit, Epineuron, Tulavi Nerve Therapeutics and Micro Leads, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avation.com | 1999 | Columbus, United States | $34.92M | – | Wearable tibial nerve stimulation device treats overactive bladder symptoms. | |
| biocircuit.com | 2016 | Atlanta, United States | $13.65M | – | Non-invasive electrophysiology devices are developed to monitor peripheral nerves. | |
| epineurontech.com | 2016 | Hamilton, Canada | – | – | Medical devices for peripheral nerve injury treatment are provided. | |
| tulavi.com | 2020 | Mountain View, United States | $4M | – | Therapeutic devices for neurally mediated diseases are developed. | |
| micro-leads.com | 2014 | Boston, United States | – | – | Micro-cuff electrodes and wireless pulse generators for neuromodulation are developed. | |
| photothera.com | 1997 | Carlsbad, United States | $80.5M | – | Provides advanced laser therapy solutions for healthcare applications. | |
| renerva.com | 2017 | Pittsburgh, United States | $1.28M | – | Implants for peripheral nerve repair are developed for injury treatment. | |
| rxfunction.com | 2010 | Minneapolis, United States | $39.95M | 30 | Wearable prostheses for sensory peripheral neuropathy patients are developed. |
Detailed competitors of Monarch Bioimplants
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Monarch Bioimplants
Complete news archive for Monarch Bioimplants
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Monarch Bioimplants
10 companies that operate in the same segment as Monarch Bioimplants (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Monarch Bioimplants
Monarch Bioimplants was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Monarch Bioimplants is headquartered in Root, Switzerland. It is registered at Root, Lucerne, Switzerland.
Monarch Bioimplants is a funded company, having raised a total of $24.93M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.52M, raised on Jul 2017.
Developer of bioimplant for peripheral nerve repair. The company has a NeuroShield device that provides non-constricting protection for the nervous system. It is made of naturally occurring Chitosan which shields nerves from further damage and promotes faster regrowth.
Monarch Bioimplants's top competitors include Avation, Tulavi Nerve Therapeutics and Epineuron.
Monarch Bioimplants has 2 investors. Key investors include FastTrack Ventures, and Global Emerging Markets.